Preview
Phase 3 trial of Cognito Therapeutics' Spectris wearable (40Hz gamma light and sound, 1 hour/day) in 550 early Alzheimer's patients over 18 months. Primary endpoint: CDR-SB cognitive score change.
The complete summary, “why it matters” analysis and the original source link are available to members.
AlzheimersBCINeurostimulationPhase 3